37 results on '"Krimbou L"'
Search Results
2. 4.P.338 Familial HDL deficiency: A cellular cholesterol transport defect
- Author
-
Genest, J., primary, Marcil, M., additional, Yu, L., additional, Batal, R., additional, Krimbou, L., additional, Boucher, B., additional, Davignon, J., additional, Oram, J.F., additional, and Cohn, J.S., additional
- Published
- 1997
- Full Text
- View/download PDF
3. 2.P.5 In vitro factors affecting the concentration of gamma-LpE (γ-LpE) in human plasma
- Author
-
Krimbou, L., primary, Tremblay, M., additional, Jacques, H., additional, Davignon, J., additional, and Cohn, J.S., additional
- Published
- 1997
- Full Text
- View/download PDF
4. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions
- Author
-
Fredenrich, A, primary, Giroux, L M, additional, Tremblay, M, additional, Krimbou, L, additional, Davignon, J, additional, and Cohn, J S, additional
- Published
- 1997
- Full Text
- View/download PDF
5. Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE.
- Author
-
Krimbou, L, primary, Tremblay, M, additional, Davignon, J, additional, and Cohn, J S, additional
- Published
- 1997
- Full Text
- View/download PDF
6. Cellular phospholipid and cholesterol efflux in high-density lipoprotein deficiency.
- Author
-
Marcil M, Bissonnette R, Vincent J, Krimbou L, Genest J, Marcil, Michel, Bissonnette, Rachel, Vincent, Jérôme, Krimbou, Larbi, and Genest, Jacques
- Published
- 2003
7. Association of apolipoprotein E with alpha2-macroglobulin in human plasma.
- Author
-
Krimbou, L, Tremblay, M, Davignon, J, and Cohn, J S
- Abstract
Apolipoprotein (apo) E plays a central role in the transport of lipids among different organs and cell types, whereas alpha2-macroglobulin (alpha2M) is responsible for the binding and inactivation of plasma proteases, as well as the transport of various cytokines, growth factors, and hormones. In the present study, evidence is presented for direct binding of apoE with alpha2M in human plasma, based on the observation that two-dimensional non-denaturing gradient gel electrophoretic separation of plasma resulted in co-migration of apoE with alpha2M in a complex intermediate in size (18.5 nm in diameter) between low (LDL) and high density lipoproteins (HDL). ApoE associated with alpha2M could be immunoprecipitated from plasma with anti-human alpha2M antiserum. Purified apoE, labeled with 125I, bound to native and methylamine-activated alpha2M (alpha2M-MA) in vitro in a time- and concentration-dependent manner. ApoE bound to alpha2M-MA with greater affinity than alpha2M. The binding of apoE to both alpha2M and alpha2M-MA did not depend on the presence of lipid. Ingestion of an oral fat load resulted in a reduction in the amount of apoE associated with alpha2M. Sphingomyelin vesicles and very low density lipoproteins (VLDL), but not phosphatidylcholine vesicles or HDL3, inhibited the in vitro binding of 125I-labeled apoE3 to alpha2M and alpha2M-MA. Binding of 125I-labeled apoE3 was also partially inhibited by an excess of platelet-derived growth factor and beta-amyloid protein, but not interferon-gamma. Subjects with an apoE 4/4 phenotype had less apoE associated with alpha2M in plasma than subjects with an apoE 3/3 or 2/2 phenotype, corresponding to reduced in vitro binding of apoE4 with alpha2M or alpha2M-MA. Although the functional significance of apoE binding to alpha2M remains to be determined, the present results demonstrate that: 1) apoE is non-covalently bound to alpha2M in human plasma, 2) alpha2M-MA has a greater capacity to bind apoE than alpha2M, 3) various proteins or lipoproteins known to bind apoE or alpha2M can potentially affect the interaction of apoE with alpha2M, and 4) association of apoE with alpha2M or alpha2M-MA is dependent on apoE phenotype.
- Published
- 1998
8. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects
- Author
-
Marcoux, C., Tremblay, M., Fredenrich, A., Jacques, H., Krimbou, L., Nakajima, K., Davignon, J., and Cohn, J. S.
- Published
- 1998
- Full Text
- View/download PDF
9. In vitro factors affecting the concentration of gamma-LpE (gamma-LpE) in human plasma.
- Author
-
Krimbou, L, Tremblay, M, Jacques, H, Davignon, J, and Cohn, J S
- Abstract
Gamma-LpE (gamma-LpE), a sphingomyelin-rich lipoprotein that contains apolipoprotein (apo) E as its only protein component, has been proposed to play a role in cellular cholesterol efflux by acting, like pre-beta1-LpA-I, as an initial acceptor of cell-derived cholesterol. In order to further characterize the presence of gamma-LpE in human plasma, we have separated gamma-LpE by two-dimensional non-denaturing polyacrylamide-gradient gel electrophoresis and detected its presence by immunoblotting with 125I-labeled polyclonal anti-apoE antibody. Five species of gamma-LpE were routinely detected in human plasma, ranging in mean particle diameter from 9.5 to 16.5 nm. The largest proportion of gamma-migrating apoE was associated with gamma-LpE having a diameter of 13.0 nm. Neither the amount of gamma-LpE apoE (representing less than 1-2% of total plasma apoE) nor the number of gamma-LpE subfractions was different in serum vs. plasma, or was affected by the presence of agents able to inhibit protein dimerization. Gamma-LpE subfractions were present in the plasma of patients having different apoE phenotypes (i.e., apoE 2/2, 3/3, or 4/4). Incubation of plasma at 37 degrees C (90 min) caused a significant decrease in plasma gamma-LpE (>80%) that was not dependent on LCAT or CETP activity. Storage (at -70 degrees C) of hypertriglyceridemic but not normolipidemic plasma resulted in an increase in gamma-LpE. Freezing of postprandial plasma samples, containing increased amounts of triglyceride-rich lipoproteins (TRL) enriched in apoE, also caused an increase in gamma-LpE. Incubation of VLDL (d < 1.006 g/ml) with lipase resulted in the production of gamma-migrating apoE. These results demonstrate that: 1) different gamma-LpE subfractions exist in human plasma; 2) the amount of apoE associated with gamma-LpE subfractions is dependent on in vitro conditions of plasma storage; and 3) TRL can act as a source of gamma-LpE apoE in vitro.
- Published
- 1998
10. 2.P.5 In vitrofactors affecting the concentration of gamma-LpE (γ-LpE) in human plasma
- Author
-
Krimbou, L., Tremblay, M., Jacques, H., Davignon, J., and Cohn, J.S.
- Published
- 1997
- Full Text
- View/download PDF
11. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g)
- Author
-
Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, and Genest J
- Published
- 2008
- Full Text
- View/download PDF
12. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile.
- Author
-
Alwaili K, Bailey D, Awan Z, Bailey SD, Ruel I, Hafiane A, Krimbou L, Laboissiere S, and Genest J
- Subjects
- Adult, Aged, Case-Control Studies, Cell Line, Cholesterol blood, Cholesterol metabolism, Coronary Artery Disease blood, Humans, Male, Middle Aged, Acute Coronary Syndrome blood, Blood Proteins metabolism, Inflammation blood, Lipoproteins, HDL blood, Proteome metabolism
- Abstract
Inflammation is a major factor underlying acute coronary syndromes (ACS). HDL particles may be remodeled, becoming functionally defective, under the inflammatory conditions seen in ACS. Shotgun proteomics was used to monitor changes in the HDL proteome between male age-matched control, stable CAD, and ACS subjects (n=10/group). HDL was isolated by ultracentrifugation and separated by 1D-gel followed by LC-MS/MS. We identified 67 HDL-associated proteins, 20 of which validated recently identified proteins including vitronectin and complement C4B, and 5 of which were novel. Using gene ontology analysis, we found that the HDL-proteome consisted of proteins involved in cholesterol homeostasis (~50%), with significant contributions by proteins involved in lipid binding, antioxidant, acute-phase response, immune response, and endopeptidase/protease inhibition. Importantly, levels of apoA-IV were significantly reduced in ACS patients, whereas levels of serum amyloid A (SAA) and complement C3 (C3) were significantly increased (spectral counting; t-test p≤0.05), as confirmed by immunoblot or ELISA. Despite differences in protein composition, ABCA1, ABCG1, and SR-BI mediated cholesterol efflux assays did not indicate that HDL from ACS patients is functionally deficient as compared to controls, when corrected for apoA-I mass. Our results support that the HDL proteome differs between control, CAD and ACS patients. Increased abundance of SAA, C3, and other inflammatory proteins in HDL from ACS patients suggests that HDL reflects a shift to an inflammatory profile which, in turn, might alter the protective effects of HDL on the atherosclerotic plaque. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010)., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
13. Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis.
- Author
-
Iatan I, Bailey D, Ruel I, Hafiane A, Campbell S, Krimbou L, and Genest J
- Subjects
- ATP Binding Cassette Transporter 1, Animals, Binding Sites, Cell Line, Cholesterol metabolism, Cricetinae, Humans, Protein Structure, Quaternary, Protein Transport, ATP-Binding Cassette Transporters chemistry, ATP-Binding Cassette Transporters metabolism, Apolipoprotein A-I metabolism, Membrane Microdomains metabolism, Phosphatidylcholines biosynthesis, Phosphatidylcholines metabolism, Protein Multimerization
- Abstract
Recent studies have identified an ABCA1-dependent, phosphatidylcholine-rich microdomain, called the "high-capacity binding site" (HCBS), that binds apoA-I and plays a pivotal role in apoA-I lipidation. Here, using sucrose gradient fractionation, we obtained evidence that both ABCA1 and [¹²⁵I]apoA-I associated with the HCBS were found localized to nonraft microdomains. Interestingly, phosphatidylcholine (PtdCho) was selectively removed from nonraft domains by apoA-I, whereas sphingomyelin and cholesterol were desorbed from both detergent-resistant membranes and nonraft domains. The modulatory role of cholesterol on apoA-I binding to ABCA1/HCBS was also examined. Loading cells with cholesterol resulted in a drastic reduction in apoA-I binding. Conversely, depletion of membrane cholesterol by methyl-β-cyclodextrin treatment resulted in a significant increase in apoA-I binding. Finally, we obtained evidence that apoA-I interaction with ABCA1 promoted the activation and gene expression of key enzymes in the PtdCho biosynthesis pathway. Taken together, these results provide strong evidence that the partitioning of ABCA1/HCBS to nonraft domains plays a pivotal role in the selective desorption of PtdCho molecules by apoA-I, allowing an optimal environment for cholesterol release and regeneration of the PtdCho-containing HCBS. This process may have important implications in preventing and treating atherosclerotic cardiovascular disease.
- Published
- 2011
- Full Text
- View/download PDF
14. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
- Author
-
Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, and Genest J
- Subjects
- Animals, Apolipoprotein A-I biosynthesis, Apolipoprotein A-I metabolism, Cells, Cultured, Chlorocebus aethiops, Cholesterol, HDL metabolism, Cricetinae, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Hep G2 Cells drug effects, Hep G2 Cells metabolism, Humans, In Vitro Techniques, Macaca fascicularis, Male, Molecular Weight, Probability, Quinazolines chemistry, Quinazolinones, Random Allocation, Risk Assessment, Apolipoprotein A-I blood, Apolipoprotein A-I drug effects, Cholesterol, HDL blood, Cholesterol, HDL drug effects, Quinazolines pharmacology
- Abstract
Objectives: The aim of this study was to determine whether a novel small molecule RVX-208 affects apolipoprotein (apo)A-I and high-density lipoprotein cholesterol (HDL-C) levels in vitro and in vivo., Background: Increased apoA-I and HDL-C levels are potential therapeutic targets for reducing atherosclerotic disease., Methods: HepG2 cells were treated with 0 to 60 mumol/l RVX-208 followed by assays for apoA-I and HDL-C production. For in vivo studies, African green monkeys (AGMs) received 15 to 60 mg/kg/day RVX-208, and the serum was analyzed for lipoprotein levels, HDL-subparticle distribution, cholesterol efflux, and activity of lipid-modifying enzymes. A phase I clinical trial was conducted in healthy volunteers (given 1 to 20 mg/kg/day of RVX-208) to assess safety, tolerability, and pharmacokinetics., Results: The RVX-208 induced apoA-I messenger ribonucleic acid and protein synthesis in HepG2 cells, leading to increased levels of pre-beta-migrating and alpha-lipoprotein particles containing apoA-I (LpA-I) in spent media. Similarly, in AGMs, RVX-208 treatment for 63 days increased serum apoA-I and HDL-C levels (60% and 97%, respectively). In addition, the levels of pre-beta(1)-LpA-I and alpha1-LpA-I HDL-subparticles were increased as well as adenosine triphosphate binding cassette AI, adenosine triphosphate binding cassette G1, and scavenger receptor class B type I-dependent cholesterol efflux. These changes were not mediated by cholesteryl-ester-transfer protein. Treatment of humans for 1 week with oral RVX-208 increased apoA-I, pre-beta-HDL, and HDL functionality., Conclusions: RVX-208 increases apoA-I and HDL-C in vitro and in vivo. In AGMs, RVX-208 raises serum pre-beta(1)-LpA-I and alpha-LpA-I levels and enhances cholesterol efflux. Data in humans point to beneficial features of RVX-208 that might be useful for treating atherosclerosis., (Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
15. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis.
- Author
-
Bailey D, Ruel I, Hafiane A, Cochrane H, Iatan I, Jauhiainen M, Ehnholm C, Krimbou L, and Genest J
- Subjects
- Animals, Apolipoprotein A-I blood, Apolipoprotein A-I metabolism, Apolipoprotein E3 blood, Apolipoprotein E3 metabolism, Apolipoproteins B blood, Apolipoproteins B chemistry, Cholesterol chemistry, Cholesterol metabolism, Cholesterol Ester Transfer Proteins genetics, Esterification, Female, Hep G2 Cells, High-Density Lipoproteins, Pre-beta administration & dosage, High-Density Lipoproteins, Pre-beta blood, High-Density Lipoproteins, Pre-beta isolation & purification, Humans, Lipoproteins blood, Lipoproteins isolation & purification, Lipoproteins, HDL administration & dosage, Lipoproteins, HDL blood, Lipoproteins, HDL chemistry, Lipoproteins, HDL isolation & purification, Male, Mice, Mice, Knockout, Phospholipid Transfer Proteins chemistry, Phospholipid Transfer Proteins genetics, Rabbits, Tangier Disease blood, Time Factors, Apolipoproteins B physiology, High-Density Lipoproteins, Pre-beta chemistry, Lipoproteins chemistry
- Abstract
The specifics of nascent HDL remodeling within the plasma compartment remain poorly understood. We developed an in vitro assay to monitor the lipid transfer between model nascent HDL (LpA-I) and plasma lipoproteins. Incubation of alpha-(125)I-LpA-I with plasma resulted in association of LpA-I with existing plasma HDL, whereas incubation with TD plasma or LDL resulted in conversion of alpha-(125)I-LpA-I to prebeta-HDL. To further investigate the dynamics of lipid transfer, nascent LpA-I were labeled with cell-derived [(3 )H]cholesterol (UC) or [(3)H]phosphatidylcholine (PC) and incubated with plasma at 37 degrees C. The majority of UC and PC were rapidly transferred to apolipoprotein B (apoB). Subsequently, UC was redistributed to HDL for esterification before being returned to apoB. The presence of a phospholipid transfer protein (PLTP) stimulator or purified PLTP promoted PC transfer to apoB. Conversely, PC transfer was abolished in plasma from PLTP(-/-) mice. Injection of (125)I-LpA-I into rabbits resulted in a rapid size redistribution of (125)I-LpA-I. The majority of [(3)H]UC from labeled r(HDL) was esterified in vivo within HDL, whereas a minority was found in LDL. These data suggest that apoB plays a major role in nascent HDL remodeling by accepting their lipids and donating UC to the LCAT reaction. The finding that nascent particles were depleted of their lipids and remodeled in the presence of plasma lipoproteins raises questions about their stability and subsequent interaction with LCAT.
- Published
- 2010
- Full Text
- View/download PDF
16. Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis.
- Author
-
Hassan HH, Bailey D, Lee DY, Iatan I, Hafiane A, Ruel I, Krimbou L, and Genest J
- Subjects
- ATP Binding Cassette Transporter 1, Animals, Cricetinae, Cytosol metabolism, Dose-Response Relationship, Drug, Endocytosis, Fibroblasts metabolism, Gene Deletion, Humans, Kinetics, Models, Biological, Mutation, Protein Structure, Tertiary, ATP-Binding Cassette Transporters metabolism, Apolipoprotein A-I metabolism, Lipoproteins, HDL metabolism
- Abstract
The molecular mechanisms underlying the apoA-I/ABCA1 endocytic trafficking pathway in relation to high density lipoprotein (HDL) formation remain poorly understood. We have developed a quantitative cell surface biotinylation assay to determine the compartmentalization and trafficking of apoA-I between the plasma membrane (PM) and intracellular compartments (ICCs). Here we report that (125)I-apoA-I exhibited saturable association with the PM and ICCs in baby hamster kidney cells stably overexpressing ABCA1 and in fibroblasts. The PM was found to have a 2-fold higher capacity to accommodate apoA-I as compared with ICCs. Overexpressing various levels of ABCA1 in baby hamster kidney cells promoted the association of apoA-I with PM and ICCs compartments. The C-terminal deletion of apoA-I Delta(187-243) and reconstituted HDL particles exhibited reduced association of apoA-I with both the PM and ICCs. Interestingly, cell surface biotinylation with a cleavable biotin revealed that apoA-I induces ABCA1 endocytosis. Such endocytosis was impaired by naturally occurring mutations of ABCA1 (Q597R and C1477R). To better understand the role of the endocytotic pathway in the dynamics of the lipidation of apoA-I, a pulse-chase experiment was performed, and the dissociation (re-secretion) of (125)I-apoA-I from both PM and ICCs was monitored over a 6-h period. Unexpectedly, we found that the time required for 50% dissociation of (125)I-apoA-I from the PM was 4-fold slower than that from ICCs at 37 degrees C. Finally, treatment of the cells with phosphatidylcholine-specific phospholipase C, increased the dissociation of apoA-I from the PM. This study provides evidence that the lipidation of apoA-I occurs in two kinetically distinguishable compartments. The finding that apoA-I specifically mediates the continuous endocytic recycling of ABCA1, together with the kinetic data showing that apoA-I associated with ICCs is rapidly re-secreted, suggests that the endocytotic pathway plays a central role in the genesis of nascent HDL.
- Published
- 2008
- Full Text
- View/download PDF
17. Carboxyl-terminal disulfide bond of acid sphingomyelinase is critical for its secretion and enzymatic function.
- Author
-
Lee CY, Tamura T, Rabah N, Lee DY, Ruel I, Hafiane A, Iatan I, Nyholt D, Laporte F, Lazure C, Wada I, Krimbou L, and Genest J
- Subjects
- Amino Acid Sequence, Animals, Cell Line, Cricetinae, Endoplasmic Reticulum enzymology, Gene Expression, Humans, Molecular Sequence Data, Mutation genetics, Protein Binding, Sequence Alignment, Sequence Homology, Amino Acid, Sphingomyelin Phosphodiesterase chemistry, Sphingomyelin Phosphodiesterase genetics, Spodoptera, Ubiquitin metabolism, Disulfides metabolism, Sphingomyelin Phosphodiesterase metabolism
- Abstract
The human acid sphingomyelinase (ASM, EC 3.1.4.12), a lysosomal and secretory protein coded by the sphingomyelin phosphodiesterase 1 (SMPD-1) gene, catalyzes the degradation of sphingomyelin (SM) to ceramide and phosphorylcholine. We examined the structural-functional properties of its carboxyl-terminus (amino acids 462-629), which harbors approximately 1/3 of all mutations discovered in the SMPD-1 gene. We created four naturally occurring mutants (DeltaR608, R496L, G577A, and Y537H) and five serial carboxyl-terminal deletion mutants (N620, N590, N570, N510, and N490). Transient transfection of the His/V5-tagged wild-type and mutant recombinant ASM in Chinese hamster ovary cells showed that all the mutants were normally expressed. Nonetheless, none of them, except the smallest deletion mutant N620 that preserved all post-translational modifications, were found capable of secretion to the medium. Furthermore, only the N620 conserved functional integrity (100% activity of the wild type); all other mutants completely lost the ability to catalyze SM hydrolysis. Importantly, cell surface biotinylation revealed that mutant DeltaR608 transfected CHO cells and fibroblasts from a compound heterozygous Niemann-Pick disease type B (NPD-B) patient (DeltaR608 and R441X) have defective translocation to the plasma membrane. Furthermore, we demonstrated that the DeltaR608 and N590 were trapped in the endoplasmic reticulum (ER) quality control checkpoint in contrast to the wild-type lysosomal localization. Interestingly, while the steady-state levels of ubiquitination were minimal for the wild-type ASM, a significant amount of Lys63-linked polyubiquitinated DeltaR608 and N590 could be purified by S5a-affinity chromatography, indicating an important misfolding in the carboxyl-terminal mutants. Altogether, we provide evidence that the carboxyl-terminus of the ASM is crucial for its protein structure, which in turns dictates the enzymatic function and secretion.
- Published
- 2007
- Full Text
- View/download PDF
18. Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis.
- Author
-
Hassan HH, Denis M, Lee DY, Iatan I, Nyholt D, Ruel I, Krimbou L, and Genest J
- Subjects
- ATP Binding Cassette Transporter 1, Binding Sites, Humans, Tangier Disease physiopathology, ATP-Binding Cassette Transporters physiology, Apolipoprotein A-I metabolism, Cell Membrane metabolism, Lipoproteins, HDL biosynthesis
- Abstract
It is well accepted that both apolipoprotein A-I (apoA-I) and ABCA1 play crucial roles in HDL biogenesis and in the human atheroprotective system. However, the nature and specifics of apoA-I/ABCA1 interactions remain poorly understood. Here, we present evidence for a new cellular apoA-I binding site having a 9-fold higher capacity to bind apoA-I compared with the ABCA1 site in fibroblasts stimulated with 22-(R)-hydroxycholesterol/9-cis-retinoic acid. This new cellular apoA-I binding site was designated "high-capacity binding site" (HCBS). Glyburide drastically reduced (125)I-apoA-I binding to the HCBS, whereas (125)I-apoA-I showed no significant binding to the HCBS in ABCA1 mutant (Q597R) fibroblasts. Furthermore, reconstituted HDL exhibited reduced affinity for the HCBS. Deletion of the C-terminal region of apoA-I (Delta187-243) drastically reduced the binding of apoA-I to the HCBS. Interestingly, overexpressing various levels of ABCA1 in BHK cells promoted the formation of the HCBS. The majority of the HCBS was localized to the plasma membrane (PM) and was not associated with membrane raft domains. Importantly, treatment of cells with phosphatidylcholine-specific phospholipase C, but not sphingomyelinase, concomitantly reduced the binding of (125)I-apoA-I to the HCBS, apoA-I-mediated cholesterol efflux, and the formation of nascent apoA-I-containing particles. Together, these data suggest that a functional ABCA1 leads to the formation of a major lipid-containing site for the binding and the lipidation of apoA-I at the PM. Our results provide a biochemical basis for the HDL biogenesis pathway that involves both ABCA1 and the HCBS, supporting a two binding site model for ABCA1-mediated nascent HDL genesis.
- Published
- 2007
- Full Text
- View/download PDF
19. New insights into the biogenesis of human high-density lipoproteins.
- Author
-
Krimbou L, Marcil M, and Genest J
- Subjects
- ATP Binding Cassette Transporter 1, ATP-Binding Cassette Transporters metabolism, Apolipoprotein A-I metabolism, Cholesterol, HDL metabolism, Humans, Lipoproteins, HDL biosynthesis
- Abstract
Purpose of Review: The interest for the human HDL system was recently revived by the identification of the ABCA1 as a critical component in the formation and maintenance of plasma HDL levels. The present review focuses on recent progress in our understanding of the basic mechanisms underlying HDL biogenesis pathways., Recent Findings: Several novel mechanisms governing ABCA1/apoA-I interactions have recently been identified: apolipoprotein A-I activates ABCA1 phosphorylation through the cAMP/protein kinase A-dependent pathway; the majority of ABCA1 exists as a tetramer in human living cell, supporting the concept that the homotetrameric ABCA1 complex constitutes the minimum functional unit for the formation of nascent HDL particles; apolipoprotein A-I has been shown to have a recycling retroendocytic pathway with uptake and resecretion of the lipidated nascent HDL particles by the cell, most likely through the ABCA1 transporter pathway; there is evidence that the speciation of nascent HDL into pre-beta and alpha-HDL is linked to specific cell lines, and occurs by both ABCA1-dependent and independent pathways., Summary: The fundamental mechanisms underlying the biogenesis, speciation and maturation of HDL remain complex and not well understood. Understanding the mechanisms governing HDL genesis at the cellular level could provide novel insights into the human atheroprotective system in health and disease.
- Published
- 2006
- Full Text
- View/download PDF
20. Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B.
- Author
-
Lee CY, Lesimple A, Denis M, Vincent J, Larsen A, Mamer O, Krimbou L, Genest J, and Marcil M
- Subjects
- Adult, Animals, CHO Cells, Cells, Cultured, Cholesterol metabolism, Cricetinae, Female, Fibroblasts metabolism, Humans, Male, Middle Aged, Niemann-Pick Diseases blood, Phospholipids metabolism, Sphingomyelin Phosphodiesterase metabolism, Sphingomyelins pharmacology, Transfection, Lipoproteins, HDL metabolism, Niemann-Pick Diseases metabolism, Sphingomyelins metabolism
- Abstract
We previously reported that human Niemann-Pick Disease type B (NPD-B) is associated with low HDL. In this study, we investigated the pathophysiology of this HDL deficiency by examining both HDL samples from NPD-B patients and nascent high density lipoprotein (LpA-I) generated by incubation of lipid-free apolipoprotein A-I (apoA-I) with NPD-B fibroblasts. Interestingly, both LpA-I and HDL isolated from patient plasma had a significant increase in sphingomyelin (SM) mass ( approximately 50-100%). Analysis of LCAT kinetics parameters (V(max) and K(m)) revealed that either LpA-I or plasma HDL from NPD-B, as well as reconstituted HDL enriched with SM, exhibited severely decreased LCAT-mediated cholesterol esterification. Importantly, we documented that SM enrichment of NPD-B LpA-I was not attributable to increased cellular mass transfer of SM or unesterified cholesterol to lipid-free apoA-I. Finally, we obtained evidence that the conditioned medium from HUVEC, THP-1, and normal fibroblasts, but not NPD-B fibroblasts, contained active secretory sphingomyelinase (S-SMase) that mediated the hydrolysis of [(3)H]SM-labeled LpA-I and HDL(3). Furthermore, expression of mutant SMase (DeltaR608) in CHO cells revealed that DeltaR608 was synthesized normally but had defective secretion and activity. Our data suggest that defective S-SMase in NPD leads to SM enrichment of HDL that impairs LCAT-mediated nascent HDL maturation and contributes to HDL deficiency. Thus, S-SMase and LCAT may act in concert and play a crucial role in the biogenesis and maturation of nascent HDL particles.
- Published
- 2006
- Full Text
- View/download PDF
21. A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians.
- Author
-
Dastani Z, Dangoisse C, Boucher B, Desbiens K, Krimbou L, Dufour R, Hegele RA, Pajukanta P, Engert JC, Genest J, and Marcil M
- Subjects
- Adolescent, Adult, Aged, Apolipoprotein A-I blood, Canada epidemiology, Child, Cholesterol, HDL blood, Coronary Disease blood, Coronary Disease ethnology, Coronary Disease genetics, Electrophoresis, Gel, Two-Dimensional, Female, France ethnology, Genetic Predisposition to Disease, Haplotypes, Humans, Male, Middle Aged, Pedigree, Polymerase Chain Reaction, Tangier Disease blood, Tangier Disease ethnology, Apolipoprotein A-I genetics, Cholesterol, HDL deficiency, Codon, Nonsense, DNA genetics, Tangier Disease genetics
- Abstract
The molecular causes of severe high-density lipoprotein cholesterol (HDL-C) deficiency was examined in a group of 54 unrelated French Canadian subjects. The lecithin:cholesterol acyl transferase (LCAT) and apolipoprotein (apo) A-I gene were analyzed in all probands by direct DNA sequencing. While no LCAT mutation was detected, a novel nonsense apoA-I mutation (E136X) was found in 3/54 probands. Genetic analysis of two kindreds showed a strong co-segregation of the apoA-I locus with the low HDL-C trait. The E136X mutation was detected in families by MaeI restriction digestion. E136X carriers (n=17) had marked HDL-C deficiency; among the nine carriers > or = 35 years old, five men had developed premature coronary artery disease (CAD). A peptide of apparent molecular weight of 14 kDa was identified in fresh plasma, the HDL fractions and lipoprotein deficient plasma from the three probands but not in normal controls (n=3), suggesting that the mutant apoA-I peptide is secreted and binds lipids. The mutation was not observed in an additional 210 chromosomes from unrelated subjects of French Canadian descent, < 60 years of age, with CAD and low HDL-C levels. We conclude that apoA-I (E136X) is a cause of HDL-C deficiency in the French Canadian population and is associated with premature CAD.
- Published
- 2006
- Full Text
- View/download PDF
22. Cellular cholesterol homeostasis in vascular endothelial cells.
- Author
-
Hassan HH, Denis M, Krimbou L, Marcil M, and Genest J
- Subjects
- ATP-Binding Cassette Transporters metabolism, Apolipoprotein A-I metabolism, Cells, Cultured, Cholesterol, HDL metabolism, Gene Expression, Humans, Scavenger Receptors, Class B metabolism, Cholesterol metabolism, Endothelium, Vascular metabolism, Homeostasis
- Abstract
Atherosclerosis is a disease of blood vessel walls that is thought to be initiated as a reaction of insults to the endothelium. The complex sequence of cellular events that begins with focal inflammation leads to the accumulation of leukocytes in the subendothelial layer and unrestricted uptake of oxidized lipoproteins by macrophages and smooth muscle cells, leading to foam cell formation. Vascular endothelial cells do not undergo the foam cell transformation and do not accumulate cholesterol in atherosclerotic plaques to the same extent as macrophages or smooth muscle cells. However, vascular endothelial cells express receptors for oxidized lipoproteins, and have the biochemical pathways for sterol synthesis and receptor-mediated endocytosis of lipoproteins. Data from the authors' laboratory show that high density lipoproteins but not lipid-free apolipoprotein A-I promote cellular cholesterol efflux in human umbilical vascular endothelial cells and human aortic endothelial cells. Gene expression microarrays were used to examine the differential expression of genes after cholesterol loading. While sterol regulatory element-binding protein-sensitive genes were downregulated, the authors identified a novel transporter, the ATP-binding cassette G1 (ABCG1) to be highly expressed in response to both cellular cholesterol loading and stimulation with the liver X receptor agonist 22-hydroxycholesterol. The ABCA1 gene and protein, the major modulator of cellular cholesterol efflux in macrophages and in peripheral and hepatic tissues, are only weakly expressed in human umbilical vascular endothelial cells and human aortic endothelial cells. These data suggest that endothelial cells maintain cholesterol homeostasis by downregulating cholesterol synthesis and low density lipoprotein receptors and by a cellular cholesterol efflux mechanism onto low-affinity but high-capacity high density lipoproteins. The role of ABC-type transporters, including ABCG1, requires further examination.
- Published
- 2006
- Full Text
- View/download PDF
23. Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines.
- Author
-
Krimbou L, Hajj Hassan H, Blain S, Rashid S, Denis M, Marcil M, and Genest J
- Subjects
- ATP Binding Cassette Transporter 1, ATP-Binding Cassette Transporters metabolism, Animals, Cell Line, Fibroblasts metabolism, Humans, Kinetics, Particle Size, Phosphatidylcholine-Sterol O-Acyltransferase metabolism, Apolipoprotein A-I metabolism, Lipoproteins, HDL biosynthesis
- Abstract
It is generally thought that the large heterogeneity of human HDL confers antiatherogenic properties; however, the mechanisms governing HDL biogenesis and speciation are complex and poorly understood. Here, we show that incubation of exogenous apolipoprotein A-I (apoA-I) with fibroblasts, CaCo-2, or CHO-overexpressing ABCA1 cells generates only alpha-nascent apolipoprotein A-I-containing particles (alpha-LpA-I) with diameters of 8-20 nm, whereas human umbilical vein endothelial cells and ABCA1 mutant (Q597R) cells were unable to form such particles. Interestingly, incubation of exogenous apoA-I with either HepG2 or macrophages generates both alpha-LpA-I and prebeta1-LpA-I. Furthermore, glyburide inhibits almost completely the formation of alpha-LpA-I but not prebeta1-LpA-I. Similarly, endogenously secreted HepG2 apoA-I was found to be associated with both prebeta1-LpA-I and alpha-LpA-I; by contrast, CaCo-2 cells secreted only alpha-LpA-I. To determine whether alpha-LpA-I generated by fibroblasts is a good substrate for LCAT, isolated alpha-LpA-I as well as reconstituted HDL [r(HDL)] was reacted with LCAT. Although both particles had similar V(max) (8.4 vs. 8.2 nmol cholesteryl ester/h/microg LCAT, respectively), the K(m) value was increased 2-fold for alpha-LpA-I compared with r(HDL) (1.2 vs. 0.7 microM apoA-I). These results demonstrate that 1) ABCA1 is required for the formation of alpha-LpA-I but not prebeta1-LpA-I; and 2) alpha-LpA-I interacts efficiently with LCAT. Thus, our study provides direct evidence for a new link between specific cell lines and the speciation of nascent HDL that occurs by both ABCA1-dependent and -independent pathways.
- Published
- 2005
- Full Text
- View/download PDF
24. Structural modification of plasma HDL by phospholipids promotes efficient ABCA1-mediated cholesterol release.
- Author
-
Hajj Hassan H, Blain S, Boucher B, Denis M, Krimbou L, and Genest J
- Subjects
- ATP Binding Cassette Transporter 1, Animals, Apolipoprotein A-I blood, Apolipoprotein A-I drug effects, Cells, Cultured, Dimyristoylphosphatidylcholine chemistry, Humans, Lipoproteins, HDL3, Liposomes chemistry, Macrophages drug effects, Macrophages metabolism, Male, Mice, Tangier Disease blood, ATP-Binding Cassette Transporters metabolism, Cholesterol metabolism, Lipoproteins, HDL blood, Lipoproteins, HDL chemistry, Phospholipids chemistry
- Abstract
It has been suggested that ABCA1 interacts preferentially with lipid-poor apolipoprotein A-I (apoA-I). Here, we show that treatment of plasma with dimyristoyl phosphatidylcholine (DMPC) multilamellar vesicles generates prebeta(1)-apoA-I-containing lipoproteins (LpA-I)-like particles similar to those of native plasma. Isolated prebeta(1)-LpA-I-like particles inhibited the binding of (125)I-apoA-I to ABCA1 more efficiently than HDL(3) (IC(50) = 2.20 +/- 0.35 vs. 37.60 +/- 4.78 microg/ml). We next investigated the ability of DMPC-treated plasma to promote phospholipid and unesterified (free) cholesterol efflux from J774 macrophages stimulated or not with cAMP. At 2 mg DMPC/ml plasma, both phospholipid and free cholesterol efflux were increased ( approximately 50% and 40%, respectively) in cAMP-stimulated cells compared with unstimulated cells. Similarly, both phospholipid and free cholesterol efflux to either isolated native prebeta(1)-LpA-I and prebeta(1)-LpA-I-like particles were increased significantly in stimulated cells. Furthermore, glyburide significantly inhibited phospholipid and free cholesterol efflux to DMPC-treated plasma. Removal of apoA-I-containing lipoproteins from normolipidemic plasma drastically reduced free cholesterol efflux mediated by DMPC-treated plasma. Finally, treatment of Tangier disease plasma with DMPC affected the amount of neither prebeta(1)-LpA-I nor free cholesterol efflux. These results indicate that DMPC enrichment of normal plasma resulted in the redistribution of apoA-I from alpha-HDL to prebeta-HDL, allowing for more efficient ABCA1-mediated cellular lipid release. Increasing the plasma prebeta(1)-LpA-I level by either pharmacological agents or direct infusions might prevent foam cell formation and reduce atherosclerotic vascular disease.
- Published
- 2005
- Full Text
- View/download PDF
25. Characterization of oligomeric human ATP binding cassette transporter A1. Potential implications for determining the structure of nascent high density lipoprotein particles.
- Author
-
Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, and Genest J
- Subjects
- ATP Binding Cassette Transporter 1, ATP-Binding Cassette Transporters analysis, Caprylates pharmacology, Case-Control Studies, Cell Compartmentation, Cell Membrane chemistry, Cells, Cultured, Fibroblasts cytology, Fluorocarbons pharmacology, Glucosides pharmacology, Humans, Lipids, Protein Structure, Quaternary, Tangier Disease pathology, ATP-Binding Cassette Transporters chemistry, ATP-Binding Cassette Transporters physiology, Apolipoprotein A-I biosynthesis
- Abstract
The oligomeric structure of ABCA1 transporter and its function related to the biogenesis of nascent apoA-I-containing particles (LpA-I) were investigated. Using n-dodecylmaltoside and perfluoro-octanoic acid combined with non-denaturing gel, the majority of ABCA1 was found as a tetramer in ABCA1-induced human fibroblasts. Furthermore, using chemical cross-linking and SDS-PAGE, ABCA1 dimers but not the tetramers were found covalently linked. Oligomeric ABCA1 was present in isolated plasma membranes as well as in intracellular compartments. Interestingly, apoA-I was found to be associated with both dimeric and tetrameric, but not monomeric, forms of ABCA1. Neither apoA-I nor lipid molecules did affect ABCA1 oligomerization. Immunoprecipitation analysis showed that oligomeric ABCA1 did not contain other associated proteins. We next investigated the relationship between the oligomeric ABCA1 complex and the structure of LpA-I. Lipid-free apoA-I incubated with normal cells generated LpA-I with diameters between 9.5 and 20 nm. Subsequent isolation of LpA-I followed by cross-linking revealed the presence of four and eight apoA-I molecules per particle, whereas apoA-I incubated with ABCA1 mutant (Q597R) cells was unable to form such particles and remained in the monomeric form. These results demonstrate that: 1) ABCA1 exists as an oligomeric complex; and 2) ABCA1 oligomerization was independent of apoA-I binding and lipid molecules. The findings that the majority of ABCA1 exists as a tetramer that binds apoA-I, together with the observation that LpA-I contains at least four molecules of apoA-I per particle, support the concept that the homotetrameric ABCA1 complex constitutes the minimum functional unit required for the biogenesis of high density lipoprotein particles.
- Published
- 2004
- Full Text
- View/download PDF
26. High-density lipoproteins: multifunctional vanguards of the cardiovascular system.
- Author
-
Marcil M, O'Connell B, Krimbou L, and Genest J Jr
- Subjects
- Cardiovascular System metabolism, Cardiovascular System physiopathology, Clinical Trials as Topic, Coronary Artery Disease epidemiology, Coronary Artery Disease metabolism, Coronary Artery Disease physiopathology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypolipidemic Agents therapeutic use, Lipoproteins, HDL drug effects, Lipoproteins, HDL physiology, Prostaglandins metabolism, Prostaglandins pharmacology, Receptors, Lipoprotein drug effects, Receptors, Lipoprotein metabolism, Vasoconstriction drug effects, Vasoconstriction physiology, Vasodilation drug effects, Vasodilation physiology, Lipoproteins, HDL metabolism
- Abstract
The plasma level of high-density lipoprotein (HDL)-cholesterol is inversely correlated with coronary artery disease, the leading cause of death worldwide. HDL particles are thought to mediate the uptake of peripheral cholesterol and, through exchange of core lipids with other lipoproteins or selective uptake by specific receptors, return this cholesterol to the liver for bile acid secretion or hormone synthesis in steroidogenic tissues. HDL particles also act on vascular processes by modulating vasomotor function, thrombosis, cell-adhesion molecule expression, platelet function, nitric oxide release, endothelial cell apoptosis and proliferation. Many of these effects involve signal transduction pathways and gene transcription. Several genetic disorders of HDLs have been characterized at the molecular level. The study of naturally occurring mutations has considerably enhanced understanding of the role of HDL particles. Some mutations causing HDL deficiency are associated with premature coronary artery disease, while others, paradoxically, may be associated with longevity. Modulation of HDL metabolism for therapeutic purposes must take into account, not only the cholesterol content of a particle but its lipid (especially phospholipid) composition, apolipoprotein content, size and charge. Current therapeutic strategies include the use of peroxisome proliferating activator receptor-alpha agonists (fibrates) that increase apolipoprotein AI production and increase lipoprotein lipase activity, statins that have a small effect on HDL-cholesterol but markedly reduce low-density lipoprotein-cholesterol, the cholesterol/HDL-cholesterol ratio and niacin that increases HDL-cholesterol. Potential therapeutic targets include inhibition of cholesteryl ester transfer protein, modulating the ATP-binding cassette A1 transporter, and decreasing HDL uptake by scavenger receptor-B1. Novel therapies include injection of purified apolipoprotien AI and short peptides taken orally, mimicking some of the biological effects of apolipoprotein AI.
- Published
- 2004
- Full Text
- View/download PDF
27. Molecular interactions between apoE and ABCA1: impact on apoE lipidation.
- Author
-
Krimbou L, Denis M, Haidar B, Carrier M, Marcil M, and Genest J Jr
- Subjects
- ATP Binding Cassette Transporter 1, Cells, Cultured, Cross-Linking Reagents, Fibroblasts, Humans, Mutation, Protein Binding, Protein Isoforms metabolism, Skin, ATP-Binding Cassette Transporters metabolism, Apolipoproteins E metabolism, Lipid Metabolism
- Abstract
Apolipoprotein E (apoE)/ABCA1 interactions were investigated in human intact fibroblasts induced with 22(R)-hydroxycholesterol and 9-cis-retinoic acid (stimulated cells). Here, we show that purified human plasma apoE3 forms a complex with ABCA1 in normal fibroblasts. Lipid-free apoE3 inhibited the binding of (125)I-apoA-I to ABCA1 more efficiently than reconstituted HDL particles (IC(50) = 2.5 +/- 0.4 microg/ml vs. 12.3 +/- 1.3 microg/ml). ApoE isoforms showed similar binding for ABCA1 and exhibited identical kinetics in their abilities to induce ABCA1-dependent cholesterol efflux. Mutation of ABCA1 associated with Tangier disease (C1477R) abolished both apoE3 binding and apoE3-mediated cholesterol efflux. Analysis of apoE3-containing particles generated during the incubation of lipid-free apoE3 with stimulated normal cells showed nascent apoE3/cholesterol/phospholipid complexes that exhibited prebeta-electrophoretic mobility with a particle size ranging from 9 to 15 nm, whereas lipid-free apoE3 incubated with ABCA1 mutant (C1477R) cells was unable to form such particles. These results demonstrate that 1). apoE association with lipids reduced its ability to interact with ABCA1; 2). apoE isoforms did not affect apoE binding to ABCA1; 3). apoE-mediated ABCA1-dependent cholesterol efflux was not affected by apoE isoforms in fibroblasts; and 4). the lipid translocase activity of ABCA1 generates apoE-containing high density-sized lipoprotein particles. Thus, ABCA1 is essential for the biogenesis of high density-sized lipoprotein containing only apoE particles in vivo.
- Published
- 2004
- Full Text
- View/download PDF
28. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter.
- Author
-
Haidar B, Denis M, Marcil M, Krimbou L, and Genest J Jr
- Subjects
- ATP Binding Cassette Transporter 1, Alitretinoin, Alleles, Animals, Biotinylation, CHO Cells, Catalytic Domain, Cell Membrane metabolism, Colforsin pharmacology, Cricetinae, Cyclic AMP-Dependent Protein Kinases chemistry, Dose-Response Relationship, Drug, Enzyme Inhibitors pharmacology, Fibroblasts metabolism, Humans, Hydroxycholesterols metabolism, Isoquinolines pharmacology, Lipid Metabolism, Mutation, Phosphorylation, Precipitin Tests, Protein Binding, Tangier Disease metabolism, Time Factors, Transfection, Tretinoin metabolism, ATP-Binding Cassette Transporters metabolism, Apolipoprotein A-I metabolism, Cyclic AMP metabolism, Signal Transduction, Sulfonamides
- Abstract
It has been suggested that the signal transduction pathway initiated by apoA-I activates key proteins involved in cellular lipid efflux. We investigated apoA-I-mediated cAMP signaling in cultured human fibroblasts induced with (22R)-hydroxycholesterol and 9-cis-retinoic acid (stimulated cells). Treatment of stimulated fibroblasts with apoA-I for short periods of time (
- Published
- 2004
- Full Text
- View/download PDF
29. Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1).
- Author
-
Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, and Genest J Jr
- Subjects
- ATP Binding Cassette Transporter 1, Alitretinoin, Apolipoprotein A-I pharmacology, Binding, Competitive, Cells, Cultured, Cholesterol metabolism, Fibroblasts, High-Density Lipoproteins, Pre-beta, Humans, Hydroxycholesterols pharmacology, Iodine Radioisotopes, Lipoproteins, HDL metabolism, Lipoproteins, HDL3, Particle Size, Phosphatidylcholines metabolism, Protein Binding drug effects, Sphingomyelin Phosphodiesterase pharmacology, Sphingomyelins metabolism, Tretinoin pharmacology, Tritium, Type C Phospholipases pharmacology, ATP-Binding Cassette Transporters metabolism, Apolipoprotein A-I metabolism, Lipid Metabolism
- Abstract
The dynamics of ABCA1-mediated apoA-I lipidation were investigated in intact human fibroblasts induced with 22(R)-hydroxycholesterol and 9-cis-retinoic acid (stimulated cells). Specific binding parameters of (125)I-apoA-I to ABCA1 at 37 degrees C were determined: K(d) = 0.65 microg/ml, B(max) = 0.10 ng/microg cell protein. Lipid-free apoA-I inhibited the binding of (125)I-apoA-I to ABCA1 more efficiently than pre-beta(1)-LpA-I, reconstituted HDL particles r(LpA-I), or HDL(3) (IC(50) = 0.35 +/- 1.14, apoA-I; 1.69 +/- 1.07, pre-beta(1)-LpA-I; 17.91 +/- 1.39, r(LpA-I); and 48.15 +/- 1.72 microg/ml, HDL(3)). Treatment of intact cells with either phosphatidylcholine-specific phospholipase C or sphingomyelinase affected neither (125)I-apoA-I binding nor (125)I-apoA-I/ABCA1 cross-linking. We next investigated the dynamics of apoA-I lipidation by monitoring the kinetic of apoA-I dissociation from ABCA1. The dissociation of (125)I-apoA-I from normal cells at 37 degrees C was rapid (t((1/2)) = 1.4 +/- 0.66 h; n = 3) but almost completely inhibited at either 15 or 4 degrees C. A time course analysis of apoA-I-containing particles released during the dissociation period showed nascent apoA-I-phospholipid complexes that exhibited alpha-electrophoretic mobility with a particle size ranging from 9 to 20 nm (designated alpha-LpA-I-like particles), whereas lipid-free apoA-I incubated with ABCA1 mutant (Q597R) cells was unable to form such particles. These results demonstrate that: 1) the physical interaction of apoA-I with ABCA1 does not depend on membrane phosphatidylcholine or sphingomyelin; 2) the association of apoA-I with lipids reduces its ability to interact with ABCA1; and 3) the lipid translocase activity of ABCA1 generates alpha-LpA-I-like particles. This process plays in vivo a key role in HDL biogenesis.
- Published
- 2004
- Full Text
- View/download PDF
30. Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol.
- Author
-
Lee CY, Krimbou L, Vincent J, Bernard C, Larramée P, Genest J Jr, and Marcil M
- Subjects
- Cholesterol, HDL genetics, Cholesterol, HDL metabolism, Female, Humans, Male, Niemann-Pick Diseases enzymology, Niemann-Pick Diseases genetics, Niemann-Pick Diseases physiopathology, Pedigree, Sequence Analysis, DNA, Cholesterol, HDL blood, Heterozygote, Sphingomyelin Phosphodiesterase genetics
- Abstract
Type A and B forms of Niemann-Pick disease (NPD) are lipid storage disorders caused by deficient activity of the enzyme acid sphingomyelinase (aSMase) and the resulting accumulation of sphingomyelin in tissues. In the present study, we investigated two family members who had been diagnosed with Type B NPD and who had a severe decrease in plasma high density lipoprotein cholesterol (HDL-C). The proband (a 48-year-old male) had an HDL-C of 0.30 mmol/l (12 mg/dl) and his sister had values of 0.45 mmol/l (17 mg/dl) with severe premature coronary artery disease (CAD). Hypertriglyceridemia was found in both cases. aSMase activity measured in skin fibroblasts appeared markedly depressed. The SMPD1 gene, coding for aSMase, was sequenced in affected subjects and all family members. Compound heterozygosity (DeltaR608 and R441X) was identified in both affected patients. Carriers of the DeltaR608 mutation tended to have moderately to severe decreased HDL-C levels, whereas carriers of the R441X mutation, although present only in young subjects (<20 years of age) had normal HDL-C levels. To investigate the cause of the low HDL-C level in these patients, we studied apoA-I-mediated cellular cholesterol efflux in fibroblasts. Unlike patients with Tangier disease, cholesterol efflux was found to be normal under the experimental conditions used in the present study. On the other hand, we observed a significant increase in the free cholesterol:esterified cholesterol ratio in HDL fraction from these patients and a decrease in endogenous lecithin-cholesterol acyltransferase (LCAT) activity, as determined by the fractional esterification rate. Taken together, these results suggest that (1) compound heterozygosity at the SMPD1 gene causes a severe decrease in aSMase activity and in HDL-C and increases the risk of CAD, (2) this lipoprotein abnormality is not attributable to defective cellular cholesterol efflux, (3) abnormal HDL composition might cause a decrease in LCAT activity and a lack of HDL maturation.
- Published
- 2003
- Full Text
- View/download PDF
31. Structural and functional properties of human plasma high density-sized lipoprotein containing only apoE particles.
- Author
-
Krimbou L, Marcil M, Chiba H, and Genest J Jr
- Subjects
- Apolipoprotein A-I blood, Apolipoprotein A-I isolation & purification, Apolipoproteins E isolation & purification, Biological Transport physiology, Cell Line, Tumor, Cholesterol blood, Cholesterol isolation & purification, Chromatography, Affinity, Electrophoresis, Gel, Two-Dimensional, Female, Humans, Lipids blood, Lipids isolation & purification, Lipoproteins, HDL isolation & purification, Lipoproteins, HDL physiology, Male, Time Factors, Apolipoproteins E blood, Lipoproteins, HDL blood
- Abstract
To investigate the metabolism of HDL-apolipoprotein E (apoE) particles in human plasma, we isolated a fraction of plasma HDL-apoEs that lack apoA-I (HDL-LpE) from subjects with apoE3/3 phenotype by immunoaffinity. Plasma HDL-LpE had a particle size ranging from 9 nm to 18.5 nm in diameter and was characterized by two-dimensional nondenaturing gradient gel electrophoresis as having either gamma-, prebeta1-, prebeta2-, or alpha-electrophoretic mobility. HDL-LpE was also present in the medium of cultured human hepatoma cell lines and monocyte-derived macrophages. The majority of apoE3 was found as a monomeric form in HDL-LpE and floated at density d > 1.21 g/ml. Plasma levels of HDL-LpE in normolipidemic, CETP-deficient, and ABCA1-deficient subjects were 0.72 +/- 0.15 mg/dl (n = 12), 1.77 +/- 0.75 mg/dl (n = 3), and 0.55 +/- 0.11 mg/dl (n = 3), respectively. The ratio of HDL-apoE containing apoA-I to HDL-LpE was significantly higher 4 h after a fat load, representing a 35 +/- 9% increase (n = 3). Isolated plasma HDL-LpE3 was as effective as apoE3, reconstituted HDL particles, or apoA-I in promoting cellular cholesterol efflux. These results demonstrate that 1) plasma HDL-LpE may have hepatogenous and macrophagic origins; 2) HDL-LpE was preserved even with large reductions in apoA-I-containing lipoproteins; 3) HDL-LpE was active in the transfer of apoE to triglyceride-rich lipoproteins, and 4) HDL-LpEs efficiently take up cell-derived cholesterol.
- Published
- 2003
- Full Text
- View/download PDF
32. Expression, regulation, and activity of ABCA1 in human cell lines.
- Author
-
Denis M, Bissonnette R, Haidar B, Krimbou L, Bouvier M, and Genest J
- Subjects
- 8-Bromo Cyclic Adenosine Monophosphate metabolism, ATP Binding Cassette Transporter 1, ATP-Binding Cassette Transporters genetics, Biological Transport, Blotting, Northern, Cell Line, Cholesterol metabolism, Dose-Response Relationship, Drug, Down-Regulation, Fibroblasts metabolism, Gene Expression Regulation, Humans, Immunoblotting, Macrophages metabolism, Monocytes metabolism, Polyisoprenyl Phosphates metabolism, RNA, Messenger metabolism, Time Factors, Transcription, Genetic, ATP-Binding Cassette Transporters biosynthesis, ATP-Binding Cassette Transporters metabolism
- Abstract
Mutations in the ATP-binding cassette transporter A1 (ABCA1) gene cause familial high-density lipoprotein deficiency and Tangier disease. ABCA1 plays a crucial role in active apolipoprotein A-I (apoA-I) lipidation, a key step in reverse cholesterol transport. We compared ABCA1 transcriptional regulation and cholesterol efflux in human skin fibroblasts, monocyte-derived macrophages and hepatocytes (HepG2). 8-Br-cAMP did not increase ABCA1 transcription in these tissues compared to mouse macrophages. We found that ABCA1 is differentially regulated among tissues. While transcription in HepG2 appears to be constitutive, sterols stimulate ABCA1 transcription in fibroblasts and monocyte-derived macrophages. ApoA-I promoted cholesterol efflux in fibroblasts, macrophages, and HepG2. Cholesterol homeostasis in fibroblasts is tightly regulated, and ABCA1 mRNA closely follows the cellular mass of free cholesterol (dose- and time-dependent manner). To further determine the mechanism used by fibroblasts to maintain sterol balance, we used a competitive inhibition approach with geranylgeranyl pyrophosphate (GGPP) to block the LXR induction pathway. GGPP blocked basal, 22-(R)-hydroxycholesterol- and cholesterol-induced ABCA1 expression. Taken together, these results demonstrate that: (1) ABCA1 expression varies among tissues, and (2) cholesterol conversion to hydroxycholesterol is an important mechanism for the maintenance of cholesterol homeostasis in fibroblasts.
- Published
- 2003
- Full Text
- View/download PDF
33. cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts.
- Author
-
Haidar B, Denis M, Krimbou L, Marcil M, and Genest J Jr
- Subjects
- ATP Binding Cassette Transporter 1, ATP-Binding Cassette Transporters biosynthesis, ATP-Binding Cassette Transporters genetics, Apolipoprotein A-I metabolism, Cyclic AMP-Dependent Protein Kinases antagonists & inhibitors, Cyclic AMP-Dependent Protein Kinases metabolism, Humans, Mutation, Phosphorylation, RNA, Messenger metabolism, Signal Transduction physiology, Tangier Disease genetics, Tangier Disease metabolism, ATP-Binding Cassette Transporters metabolism, Cholesterol metabolism, Cyclic AMP metabolism, Fibroblasts metabolism
- Abstract
ATP-binding cassette transporter A1 (ABCA1) plays a crucial role in apoA-I lipidation, a key step in reverse cholesterol transport. cAMP induces apoA-I binding activity and promotes cellular cholesterol efflux. We investigated the role of the cAMP/protein kinase A (PKA) dependent pathway in the regulation of cellular cholesterol efflux. Treatment of normal fibroblasts with 8-bromo-cAMP (8-Br-cAMP) increased significantly apoA-I-mediated cholesterol efflux, with specificity for apoA-I, but not for cyclodextrin. Concomitantly, 8-Br-cAMP increased ABCA1 phosphorylation in a time-dependent manner. Maximum phosphorylation was reached in <10 min, representing a 260% increase compared to basal ABCA1 phosphorylation level. Forskolin, a known cAMP regulator, increased both cellular cholesterol efflux and ABCA1 phosphorylation. In contrast, H-89 PKA inhibitor reduced cellular cholesterol efflux by 70% in a dose-dependent manner and inhibited almost completely ABCA1 phosphorylation. To determine whether naturally occurring mutants of ABCA1 may affect its phosphorylation activity, fibroblasts from subjects with familial HDL deficiency (FHD, heterozygous ABCA1 defect) and Tangier disease (TD, homozygous/compound heterozygous ABCA1 defect) were treated with 8-Br-cAMP or forskolin. Cellular cholesterol efflux and ABCA1 phosphorylation were increased in FHD but not in TD cells. Taken together, these findings provide evidence for a link between the cAMP/PKA-dependent pathway, ABCA1 phosphorylation, and apoA-I mediated cellular cholesterol efflux.
- Published
- 2002
- Full Text
- View/download PDF
34. Interaction of lecithin:cholesterol acyltransferase (LCAT).alpha 2-macroglobulin complex with low density lipoprotein receptor-related protein (LRP). Evidence for an alpha 2-macroglobulin/LRP receptor-mediated system participating in LCAT clearance.
- Author
-
Krimbou L, Marcil M, Davignon J, and Genest J Jr
- Subjects
- Apolipoprotein E3, Apolipoproteins E genetics, Binding Sites, Carcinoma, Hepatocellular, Genotype, Humans, Kinetics, Liver Neoplasms, Low Density Lipoprotein Receptor-Related Protein-1, Male, Phosphatidylcholine-Sterol O-Acyltransferase isolation & purification, Protein Binding, Receptors, Immunologic chemistry, Receptors, Immunologic isolation & purification, Receptors, LDL metabolism, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Tumor Cells, Cultured, Type C Phospholipases metabolism, alpha-Macroglobulins isolation & purification, Phosphatidylcholine-Sterol O-Acyltransferase chemistry, Phosphatidylcholine-Sterol O-Acyltransferase metabolism, Receptors, Immunologic metabolism, alpha-Macroglobulins chemistry, alpha-Macroglobulins metabolism
- Abstract
The reaction of lecithin:cholesterol acyltransferase (LCAT) with high density lipoproteins (HDL) is of critical importance in reverse cholesterol transport, but the structural and functional pathways involved in the regulation of LCAT have not been established. We present evidence for the direct binding of LCAT to alpha(2)-macroglobulin (alpha(2)M) in human plasma to form a complex 18.5 nm in diameter. Forty percent of plasma LCAT-HDL was associated with alpha(2)M; moreover, most of the LCAT in cerebrospinal fluid and in the medium of cultured human hepatoma cell line was associated with alpha(2)M. Purified recombinant human LCAT (rLCAT) labeled with (125)I bound to native and methylamine-activated alpha(2)M (alpha(2)M-MA) in vitro in a time- and concentration-dependent manner, and this binding did not depend on the presence of lipid. rLCAT bound to alpha(2)M-MA with greater affinity than to alpha(2)M. Furthermore, rLCAT did not activate alpha(2)M as phosphatidylcholine-specific phospholipase C does. Reconstituted HDL particles (LpA-I) inhibited the binding of rLCAT to alpha(2)M more efficiently than native HDL(3) did. LCAT associated with alpha(2)M was enzymatically inactive under both endogenous and exogenous assay conditions. Purified rLCAT alone did not bind to low density lipoprotein receptor-related protein (LRP) as lipoprotein lipase (LPL) does; however, when rLCAT was combined with alpha(2)M-MA to form a complex, binding, internalization, and degradation of rLCAT took place in LRP-expressing cells (LRP (+/+)) but not in cells deficient in LRP (LRP (-/-)). It is concluded that the binding of LCAT to alpha(2)M inhibits its enzymatic activity. Furthermore, the finding supports the possibility that the LRP receptor can act in vivo to mediate clearance of the LCAT-alpha(2)M complex and may significantly influence the bioavailability of LCAT.
- Published
- 2001
- Full Text
- View/download PDF
35. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency.
- Author
-
Marcil M, Yu L, Krimbou L, Boucher B, Oram JF, Cohn JS, and Genest J Jr
- Subjects
- Adult, Amino Acid Sequence, Apolipoprotein A-I metabolism, Biological Transport, Cells, Cultured, Cholesterol Esters metabolism, Cholesterol, HDL blood, DNA-Binding Proteins, Female, Humans, Lipoproteins, HDL metabolism, Lipoproteins, HDL3, Male, Membrane Proteins, Middle Aged, Molecular Sequence Data, RNA, Messenger metabolism, RNA-Binding Proteins genetics, Carrier Proteins, Cholesterol metabolism, Cholesterol, HDL deficiency, Fibroblasts metabolism, Lipoproteins, HDL deficiency
- Abstract
Familial high density lipoprotein (HDL) deficiency (FHD) is a genetic lipoprotein disorder characterized by a severe decrease in the plasma HDL cholesterol (-C) level (less than the fifth percentile). Unlike Tangier disease, FHD is transmitted as an autosomal dominant trait. FHD subjects have none of the clinical manifestations of Tangier disease (lymphoid tissue infiltration with cholesteryl esters and/or neurological manifestations). Plasmas from FHD subjects contain pre-beta-migrating HDLs but are deficient in alpha-migrating HDLs. We hypothesized that a reduced HDL-C level in FHD is due to abnormal transport of cellular cholesterol to the plasma membrane, resulting in reduced cholesterol efflux onto nascent HDL particles, leading to lipid-depleted HDL particles that are rapidly catabolized. Cellular cholesterol metabolism was investigated in skin fibroblasts from FHD and control subjects. HDL3- and apolipoprotein (apo) A-I-mediated cellular cholesterol and phosphatidylcholine efflux was examined by labeling cells with [3H]cholesterol and [3H]choline, respectively, during growth and cholesterol loading during growth arrest. FHD cells displayed an approximately 25% reduction in HDL3-mediated cellular cholesterol efflux and an approximately 50% to 80% reduction in apoA-I-mediated cholesterol and phosphatidylcholine efflux compared with normal cells. Cellular cholesterol ester levels were decreased when cholesterol-labeled cells were incubated with HDL3 in normal cells, but cholesterol ester mobilization was significantly reduced in FHD cells. HDL3 binding to fibroblasts and the possible role of the HDL binding protein/vigilin in FHD were also investigated. No differences were observed in 125I-HDL3 binding to LDL-loaded cells between FHD and control cells. HDL binding protein/vigilin mRNA levels and its protein expression were constitutively expressed in FHD cells and could be modulated ( approximately 2-fold increase) by elevated cellular cholesterol in normal cells. In conclusion, FHD is characterized by reduced HDL3- and apoA-I-mediated cellular cholesterol efflux. It is not associated with abnormal cellular HDL3 binding or a defect in a putative HDL binding protein.
- Published
- 1999
- Full Text
- View/download PDF
36. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I.
- Author
-
Batal R, Tremblay M, Krimbou L, Mamer O, Davignon J, Genest J Jr, and Cohn JS
- Subjects
- Apolipoproteins blood, Deuterium, Electrophoresis, Gel, Two-Dimensional, Humans, Isoelectric Focusing, Kinetics, Leucine, Lipids blood, Lipoproteins blood, Lipoproteins, HDL blood, Apolipoprotein A-I metabolism, Apolipoprotein A-II metabolism, Tangier Disease blood
- Abstract
We have previously described patients with familial high density lipoprotein (HDL) deficiency (FHD) having a marked reduction in the plasma concentration of HDL cholesterol and apolipoprotein (apo) A-I but lacking clinical manifestations of Tangier disease or evidence of other known causes of HDL deficiency. To determine whether FHD in these individuals was associated with impaired HDL production or increased HDL catabolism, we investigated the kinetics of plasma apoA-I and apoA-II in two related FHD patients (plasma apoA-I, 17 and 37 mg/dL) and four control subjects (apoA-I, 126+/-18 mg/dL, mean+/-SD) by using a primed constant infusion of deuterated leucine. Kinetic analysis of plasma apolipoprotein enrichment curves demonstrated that mature plasma apoA-I production rates (PRs) were similar in patients and control subjects (7.9 and 9.1 versus 10.5+/-1.7 mg x kg[-1] x d[-1]). Residence times (RTs) of mature apoA-I were, however, significantly less in FHD patients (0.79 and 1.66 days) compared with controls (5.32+/-1.05 days). Essentially normal levels of plasma proapoA-I (the precursor protein of apoA-I) in FHD patients were associated with normal plasma proapoA-I PRs (7.8 and 10.4 versus 10.9+/-2.6 mg x kg[-1] x d[-1]) and proapoA-I RTs (0.18 and 0.15 versus 0.16+/-0.03 day). The RTs of apoA-II were, however, less in patients (3.17 and 2.92 days) than control subjects (7.24+/-0.71 days), whereas the PRs of apoA-II were similar (1.8 and 1.9 versus 1.7+/-0.2 mg x kg[-1] x d[-1]). Increased plasma catabolism of apoA-II in FHD patients was associated with the presence in plasma of abnormal apoA-II-HDL (without apoA-I). These results demonstrate that FHD in our patients is characterized, like Tangier disease, by hypercatabolism of mature apoA-I and apoA-II, but unlike Tangier disease, by essentially normal plasma catabolism and concentration of proapoA-I.
- Published
- 1998
- Full Text
- View/download PDF
37. Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization.
- Author
-
Marcil M, Boucher B, Krimbou L, Solymoss BC, Davignon J, Frohlich J, and Genest J Jr
- Subjects
- Adolescent, Adult, Aged, Apolipoprotein A-I blood, Apolipoproteins genetics, Base Sequence, Canada, Child, Chromosomes, Human, Pair 11, Coronary Disease genetics, DNA Primers chemistry, Female, Genes, Humans, Lipids blood, Lipoproteins, HDL genetics, Male, Middle Aged, Molecular Sequence Data, Pedigree, Phosphatidylcholine-Sterol O-Acyltransferase blood, Polymorphism, Restriction Fragment Length, Lipoproteins, HDL deficiency
- Abstract
A decreased level of HDL cholesterol (HDL-C) is the most common lipoprotein abnormality seen in people with premature coronary artery disease (CAD). In many cases, HDL-C reduction in patients with CAD may be the result of increased apo B-containing lipoprotein production by the liver with secondary hypoalphalipoproteinemia. Primary hypoalphalipoproteinemia is seen in approximately 4% of people with CAD. We report findings in four subjects with severe familial HDL deficiency (HDL-C << 5th percentile for age and sex; 0.08 to 0.38 mmol/L) in three French-Canadian kindreds with autosomal codominant inheritance. By inclusion criteria, all four subjects had normal fasting triglycerides and none were diabetic. HDL particle size by gradient gel electrophoresis revealed small HDL particles (estimated Stokes' diameter, 8.14 to 8.30 nm). Apo AI analysis by polyacrylamide gel electrophoresis and use of isoelectrofocusing gels in affected subjects revealed normal molecular weight (28.3 kD) and normal isoelectrofocusing point but a relative increase in proapoliprotein AI, with near-normal levels of proapolipoprotein AI in plasma, suggesting normal secretion of apo AI. Quantitative Southern blot analysis of the apo AI-CIII-AIV gene cluster reveals no gene rearrangements or allele deletion. Haplotypes of the apo AI gene, determined by use of the restriction enzymes Pst I, Xmn I, and Sst I and of the apo AII gene by use of the enzyme Msp I, did not reveal segregation of the low HDL-C trait with either the apo AI or the AII gene. Sequence analysis of the promoter region of the apo AI gene reveals heterozygosity for guanine-to-adenine substitution at position 76 in two kindreds with no evidence of segregation with the low HDL trait. None of the patients had mutations of the lipoprotein lipase gene common in subjects of French-Canadian descent. Haplotype analysis of the lipoprotein lipase gene did not show segregation with the low HDL trait. Plasma lecithin: cholesterol acyltransferase (LCAT) activity was found to be within normal levels in affected subjects and in nonaffected first-degree relatives. None of the affected subjects had clinical manifestations of Tangier disease. Two of the four cases examined, both men, had severe CAD and had undergone revascularization procedures. The third is a younger brother of one of these probands and the fourth is a 30-year-old woman, and both were free of clinical CAD. However, in none of the families did the low HDL trait unequivocally cosegregate with CAD.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.